Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioAge Labs, Inc. ( (BIOA) ) has shared an announcement.
On June 5, 2025, BioAge Labs, Inc. held its Annual Meeting of Stockholders where stockholders approved the election of three Class I Directors, Kristen Fortney, Ph.D., Eric Morgen, M.D., and Vijay Pande, Ph.D., to serve until 2028. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (BIOA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Underperform.
BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
BioAge Labs, Inc. operates in the biotechnology industry, focusing on developing therapies to extend healthy lifespan by targeting the molecular causes of aging.
Average Trading Volume: 283,651
Technical Sentiment Signal: Hold
Current Market Cap: $159.5M
See more data about BIOA stock on TipRanks’ Stock Analysis page.